EuroPCR

PCR is a European organization dedicated to education and information in the field of interventional cardiology and minimally invasive transcatheter procedures. Its activities cover a large spectrum, from the organization of annual courses in Europe, Asia, the Middle East and Africa, to editing a scientific journal, publishing textbooks as well as providing training seminars on thematic subjects. For more information, visit https://www.pcronline.com/Courses/EuroPCR.

TAVR or SAVR? ChatGPT could help cardiologists decide
Researchers asked ChatGPT to make treatment decisions for patients with severe aortic stenosis, comparing its answers to the recommendations of a full heart team.
Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR
Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice.
EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes
Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris.
Redo TAVR appears feasible for most patients with supra-annular, self-expanding Evolut valves
Researchers evaluated data from more than 200 patients who underwent redo TAVR, noting that women and patients with a higher BMI faced a higher risk of coronary flow compromise.
New self-expanding TAVR valve shows promise
It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device.

Many operators don’t use FFR, iFR because they think angiography is good enough

Assessment of coronary physiology to guide revascularization decisions has been linked to lower adverse event rates than using angiography alone, but the adoption of techniques such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) continues to lag behind guideline recommendations.

May 23, 2018

Renal denervation linked to significant drops in blood pressure

Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.

May 23, 2018

New ORBITA data: Freedom from angina, stress echos improved with PCI

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

May 22, 2018

HeartFlow Analysis Demonstrates Highest Diagnostic Performance for Detecting Heart Disease Compared to Other Non-Invasive Tests

PARIS, May 22, 2018 — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests.

May 22, 2018

FFR-guided PCI linked to better 5-year outcomes than medical therapy

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

May 22, 2018

Edwards gains CE mark for first transcatheter tricuspid treatment

Edwards Lifesciences has received CE mark approval for its Cardioband Tricuspid Valve Reconstruction System, making it the first commercially available transcatheter therapy to treat tricuspid valve heart disease.

May 1, 2018

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

April 9, 2018

HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology

REDWOOD CITY, Calif., March 1, 2018 — HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement with Cedars-Sinai in Los Angeles for AutoPlaque technology, a software tool used to detect and characterize coronary artery plaque based on coronary computed tomography angiography (CCTA) images.

March 2, 2018

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

EuroPCR

TAVR or SAVR? ChatGPT could help cardiologists decide

Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR

EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes

Redo TAVR appears feasible for most patients with supra-annular, self-expanding Evolut valves

New self-expanding TAVR valve shows promise

Around the web